Publications
Detailed Information
ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Han, Hye-Suk | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T12:01:57Z | - |
dc.date.available | 2021-01-31T12:01:57Z | - |
dc.date.created | 2020-07-28 | - |
dc.date.created | 2020-07-28 | - |
dc.date.issued | 2012-08 | - |
dc.identifier.citation | Oncology, Vol.83 No.4, pp.218-227 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.other | 109162 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173222 | - |
dc.description.abstract | Objective: The aim of this study was to elucidate clinical implications of ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer (MBC) after taxane plus trastuzumab (TH) chemotherapy. Methods: Using genomic DNA samples extracted from mononuclear cells of consecutive patients with HER2-positive MBC who received first-line TH, we analyzed five polymorphisms (ABCB1 1236C>T, ABCB1 2677G>T/A, ABCB1 3435C>T, FCGR2A 131H/R, and FCGR3A 158V/F) and then correlated them with the response rate, progression-free survival (PFS), overall survival (OS), and adverse events of patients. Results: A total of 57 women were analyzed. The median age was 46 years (range 27-72). ABCB1 2677T carriers had a longer PFS (p = 0.037) along with a tendency toward a longer OS (p = 0.057). ABCB1 3435CC genotype carriers had a shorter PFS (p = 0.039) along with a tendency toward a shorter OS (p = 0.093). In combined analysis, PFS was significantly longer in ABCB1 1236CC and/or 2677TT carriers compared to the others (p = 0.006). FCGR2A 131H/R and FCGR3A 158V/F polymorphisms were not significantly associated with response rate, PFS, and OS. Conclusions: Our data support that ABCB1 polymorphisms may predict PFS after first-line TH chemotherapy in patients with HER2-positive MBC. In contrast, FCGR2A 131H/R and FCGR3A 158V/F polymorphisms could not predict treatment outcomes. Copyright (C) 2012 S. Karger AG, Basel | - |
dc.language | 영어 | - |
dc.publisher | S. Karger AG | - |
dc.title | ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1159/000341359 | - |
dc.citation.journaltitle | Oncology | - |
dc.identifier.wosid | 000308134900006 | - |
dc.identifier.scopusid | 2-s2.0-84865054217 | - |
dc.citation.endpage | 227 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 218 | - |
dc.citation.volume | 83 | - |
dc.identifier.sci | 000308134900006 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | FC-GAMMA-RIIIA | - |
dc.subject.keywordPlus | SINGLE NUCLEOTIDE POLYMORPHISMS | - |
dc.subject.keywordPlus | C-RECEPTOR POLYMORPHISMS | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANCE | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PREDICT RESPONSE | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | 3435C-GREATER-THAN-T | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | MDR1 | - |
dc.subject.keywordAuthor | ABCB1 | - |
dc.subject.keywordAuthor | FCGR2A | - |
dc.subject.keywordAuthor | FCGR3A | - |
dc.subject.keywordAuthor | Polymorphism | - |
dc.subject.keywordAuthor | Taxane | - |
dc.subject.keywordAuthor | Trastuzumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.